Technology insight:: Calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease

被引:56
|
作者
Lundberg, J [1 ]
Hellström, PM
Fagerhol, MK
Weitzberg, E
Roseth, AG
机构
[1] Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden
[2] Ullevaal Univ Hosp, Oslo, Norway
[3] Aker Univ Hosp, Oslo, Norway
来源
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY | 2005年 / 2卷 / 02期
关键词
calprotectin; fecal marker; inflammatory bowel disease; lactoferrin; nitric oxide;
D O I
10.1038/ncpgasthep0094
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Distinguishing patients with inflammatory bowel disease from those with irritable bowel syndrome can be difficult. A simple and reliable test that detects intestinal inflammation would therefore be very useful in the clinic. If such a test parameter correlated with the intensity of the inflammatory reaction it could also be used to monitor disease activity. Calprotectin, lactoferrin and nitric oxide are produced and released locally in much greater quantities in the inflamed gut than in the noninflamed gut. These compounds can be readily measured in fecal samples (calprotectin and lactoferrin) or directly in the intestinal lumen (nitric oxide gas). Here, we discuss what is known about these markers, how they could be used in clinical practice and how they can complement existing techniques used for the diagnosis and monitoring of inflammatory bowel disease.
引用
收藏
页码:96 / 102
页数:7
相关论文
共 50 条
  • [21] The status of diagnostic markers for inflammatory bowel disease
    Beniwal P.
    Harrell L.
    Current Gastroenterology Reports, 2010, 12 (6) : 479 - 484
  • [22] Fecal markers in the management of inflammatory bowel disease
    Dai, Cong
    Jiang, Min
    Sun, Ming-Jun
    POSTGRADUATE MEDICINE, 2018, 130 (07) : 597 - 606
  • [23] The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease
    Suarez Ferrer, Cristina
    Abadia Barno, Marta
    Martin Arranz, Eduardo
    Jochems, Andrea
    Garcia Ramirez, Laura
    Poza Cordon, Joaquin
    Jaquotot Herranz, Marta
    Cerpa Arencibia, Alberto
    Martin Arranz, Maria Dolores
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2019, 111 (10) : 744 - 749
  • [24] The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease
    Kwapisz, Lukasz
    Gregor, Jamie
    Chande, Nilesh
    Yan, Brian
    Ponich, Terry
    Mosli, Mahmoud
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (08) : 846 - 850
  • [25] Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease
    Bunn, SK
    Bisset, WM
    Main, MJC
    Golden, BE
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2001, 32 (02) : 171 - 177
  • [26] The role and utility of faecal markers in inflammatory bowel disease
    Lehmann, Frank S.
    Burri, Emanuel
    Beglinger, Christoph
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2015, 8 (01) : 23 - 36
  • [27] Salivary calprotectin is elevated in patients with active inflammatory bowel disease
    Majster, Mirjam
    Almer, Sven
    Bostrom, Elisabeth A.
    ARCHIVES OF ORAL BIOLOGY, 2019, 107
  • [28] Compliance with the faecal calprotectin test in patients with inflammatory bowel disease
    Marechal, Chloe
    Aimone-Gastin, Isabelle
    Baumann, Cedric
    Dirrenberger, Bastien
    Gueant, Jean-Louis
    Peyrin-Biroulet, Laurent
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2017, 5 (05) : 702 - 707
  • [29] Increased urinary nitrite, a marker of nitric oxide, in active inflammatory bowel disease
    Goggins, MG
    Shah, SA
    Goh, J
    Cherukuri, A
    Weir, DG
    Kelleher, D
    Mahmud, N
    MEDIATORS OF INFLAMMATION, 2001, 10 (02) : 69 - 73
  • [30] The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity
    Lee, Yang Woon
    Lee, Kang-Moon
    Lee, Ji Min
    Chung, Yoon Yung
    Kim, Dae Bum
    Kim, Yeon Ji
    Chung, Woo Chul
    Paik, Chang-Nyol
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (01) : 72 - 80